Condition: Congenital Pseudarthrosis of Tibia · Sponsor: Novadip Biosciences
The purpose of this study is to assess the efficacy and safety of NVD003 in pediatric participants with unilateral Congenital Pseudarthrosis of the Tibia (CPT) compared with iliac crest bone graft (ICBG) at 12 months post graft surgery.
This description comes directly from the study's public registry record.
Judy Ashworth, MD · 224-713-6154 · clinical@novadip.com
Lola TOME · +447468479913 · regulatory@novadip.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital, Inc. | Phoenix, Arizona, United States | Recruiting |
| Loma Linda University Health | Loma Linda, California, United States | Recruiting |
| LifeBridge Health - International Center for Limb Lengthening | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Cliniques Universitaires Saint-Luc ASBL (CUSCL) | Brussels, Brussels Capital, Belgium | Recruiting |
| CHU Amiens-Picardie | Amiens, Picardie, France | Recruiting |
| Hospital Sant Joan de Déu | Esplugues de Llobregat, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07112443